- Home
- TELA
TELA
TELA Bio Inc.
as 05-08-2025 4:00pm EST
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 36.4M | IPO Year: | 2019 |
| Target Price: | $6.00 | AVG Volume (30 days): | 85.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $6.50 | Next Earning Date: | 05-08-2025 |
| Revenue: | $69,300,000 | Revenue Growth: | 18.56% |
| Revenue Growth (this year): | 25.9% | Revenue Growth (next year): | 23.00% |
Latest TELA Bio Inc. News
TELA Breaking Stock News: Dive into TELA Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
TELA Bio Inc (TELA) Q1 2025 Earnings Report Preview: What to Expect
Simply Wall St.
7 days ago
Favourable Signals For TELA Bio: Numerous Insiders Acquired Stock
GuruFocus.com
17 days ago
TELA Bio Inc (TELA) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges with ...
GlobeNewswire
21 days ago
TELA Bio to Announce First Quarter 2025 Financial Results
GlobeNewswire
a month ago
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
Simply Wall St.
2 months ago
TELA Bio Full Year 2024 Earnings: Revenues Disappoint
MT Newswires
2 months ago
Sector Update: Health Care
GuruFocus.com
2 months ago
TELA Bio Shares Drop 43% After Weak Q4 Growth, High Sales Turnover
Compare TELA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TELA TELA Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.